Metalloprotein inhibitors

Details Metalloprotein inhibitors Metalloprotein inhibitors

2011-08-30

2011-08-30

Chandrakumar, Nizal (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C549S418000

Reexamination Certificate

active

08008510

ABSTRACT:
The present invention relates to metalloprotein inhibitors comprising:a. an organic substituent and at least one zinc binding group (ZBG) covalently attached thereto; orb. a ZBG substituted by a side chain wherein the ZBG is of formula (I):wherein X is O or S and each R1, R2, R3, and R4is individually hydrogen or an organic radical. The metalloprotein inhibitors are useful for preventing or treating a pathological disease, condition, or symptom that is associated with pathological metalloprotein activity and/or that is alleviated by inhibition of said activity.

REFERENCES:
patent: 4585780 (1986-04-01), Hider et al.
patent: 5981496 (1999-11-01), Cohen et al.
patent: 6552073 (2003-04-01), Leblanc et al.
patent: 6825204 (2004-11-01), Liu
patent: 6932960 (2005-08-01), Liu
patent: 7579486 (2009-08-01), Puerta et al.
patent: 7705164 (2010-04-01), Puerta et al.
patent: 7786316 (2010-08-01), Puerta et al.
patent: 2004/0063673 (2004-04-01), Johnson
patent: 2007/0117848 (2007-05-01), Puerta et al.
patent: 2008/0103129 (2008-05-01), Zhang et al.
patent: 2008/0161362 (2008-07-01), Puerta et al.
patent: 2009/0286987 (2009-11-01), Puerta et al.
patent: 1006112 (2000-06-01), None
patent: WO-2004/110442 (2004-12-01), None
patent: WO-2005/110399 (2005-11-01), None
patent: WO-2006/028523 (2006-03-01), None
“U.S. Appl. No. 11/554,475, Preliminary Amendment filed Oct. 22, 2007”, 7 pgs.
“U.S. Appl. No. 11/554,475, Response filed Jan. 9, 2009 to Final Office Action mailed Nov. 12, 2008”, 17 pgs.
“U.S. Appl. No. 11/554,475, Final Office Action mailed Feb. 4, 2009”, 7 pgs.
“U.S. Appl. No. 11/554,475, Advisory Action mailed May 15, 2009”, 3 pgs.
“U.S. Appl. No. 11/554,475, Final Office Action mailed Nov. 12, 2008”, 11 pgs.
“U.S. Appl. No. 11/554,475, Interview Summary of Jun. 3, 2008”, 1 pg.
“U.S. Appl. No. 11/554,475, Non-Final Office Action mailed Jun. 19, 2008”, 10 pgs.
“U.S. Appl. No. 11/554,475, Notice of Allowance mailed Jun. 3, 2009”, 6 pgs.
“U.S. Appl. No. 11/554,475, Response filed Apr. 21, 2009 to Final Office Action mailed Feb. 4, 2009”, 10 pgs.
“U.S. Appl. No. 11/554,475, Response filed Apr. 18, 2008 to Restriction Requirement mailed Feb. 26, 2008”, 10 pgs.
“U.S. Appl. No. 11/554,475, Restriction Requirement mailed Feb. 26, 2008”, 8 pgs.
“U.S. Appl. No. 11/554,475, Summary of Interview Under 37 C.F.R. § 1,133(b) filed Jul. 9, 2008”, 1 pg.
“U.S. Appl. No. 11/554,475, Amendment and Response filed Sep. 17, 2008 to Non-Final Office Action mailed Jun. 19, 2008”, 11 pgs.
“U.S. Appl. No. 11/568,505, Preliminary Amendment mailed Oct. 30, 2006”, 11 pgs.
“U.S. Appl. No. 11/568,505, Supplemental Preliminary Amendment filed Oct. 26, 2007”, 9 pgs.
“U.S. Appl. No. 11/568,505, Second Preliminary Amendment filed Aug. 20, 2007”, 10 pgs.
“U.S. Appl. No. 11/568,505, Notice of Allowance Mailed Dec. 7, 2009”, 6 pgs.
“U.S. Appl. No. 11/568,505, Final Office Action mailed Oct. 21, 2009”, 8 pgs.
“U.S. Appl. No. 11/568,505, Non-Final Office Action mailed Nov. 3, 2008”, 12 pgs.
“U.S. Appl. No. 11/568,505, Non-Final Office Action mailed Feb. 25, 2009”, 16 pgs.
“U.S. Appl. No. 11/568,505, Response filed Jul. 23, 2009 to Non Final Office Action mailed Feb. 25, 2009”, 26 pgs.
“U.S. Appl. No. 11/568,505, Response filed Oct. 17, 2008 to Restriction Requirement mailed Jun. 19, 2008”, 15 pgs.
“U.S. Appl. No. 11/568,505, Response filed Nov. 6, 2009 to Final Office Action mailed Oct. 21, 2009”, 12 pgs.
“U.S. Appl. No. 11/568,505, Response filed Feb. 2, 2009 to Non-Final Office Action mailed Nov. 3, 2008”, 21 pgs.
“U.S. Appl. No. 11/568,505, Restriction Requirement mailed Jun. 19, 2008”, 7 pgs.
“U.S. Appl. No. 12/503,190, Non-Final Office Action mailed Jan. 12, 2010”, 4 pgs.
“U.S. Appl. No. 12/503,190, Preliminary Amendment filed Nov. 19, 2009”, 5 pgs.
“U.S. Appl. No. 12/503,190, Response filed Feb. 11, 2010 to Non Final Office Action mailed Jan. 12, 2010”, 7 pgs.
“European Applicatiion Serial No. 05818191.8, Communication Pursuant to Article 96(2)EPC mailed Jul. 5, 2007”, 4 pgs.
“European Applicatiion Serial No. 05818191.8, Response filed Nov. 7, 2007 to Communication mailed Jul. 5, 2007”, 20 pgs.
“European Application Serial No. 05818191.8, Communication mailed Aug. 7, 2009”, 4 pgs.
“European Application Serial No. 05818191.8, Response filed Jan. 22, 2010 to Communication mailed Aug. 7, 2009”, 8 pgs.
“International Application Serical No. PCT/US2005/014747, International Search Report mailed Mar. 10, 2006”, 6 pgs.
“International Application Serial No. PCT/US2005/014747, Written Opinion mailed Mar. 10, 2006”, 6 pgs.
Atkinson, J. G., et al., “Kojic Amine—A Novel γ-Aminobutyric Acid Analogue”,Journal of Medicinal Chemistry, 22 (1), (1979), 99-106.
Aytemir, M. D., et al., “Synthesis and Evaluation of Antimicrobial Activity of New 3-Hydroxy-6-methyl-4-xox-4H-pyran-2-carboxamide Derivatives”,Turkish Journal of Chemistry, 27(6), (2003), 757-764.
Aytemir, M. D., et al., “Synthesis of New Antimicrobial Agents; Amide Derivatives of Pyranones and Pyridinones”,Turk. J. Chem., 27, (2003), 445-452.
Beckett, R. P., et al., “Matrix Metalloproteinase Inhibitors 1998”,Expert Opinion on Therapeutic Patents, 8(3), (Mar. 1998), 259-282.
Beckett, R. P., et al., “Recent Advances in Matrix Metalloproteinase Inhibitor Research”,Drug Discovery Today, 1(1), (Jan. 1996), 16-26.
Belonosov, I. S., et al., “4—Pyronecarboxylic acids and their transformations”,Zhumai Prikladnoi Khimii( Sankt-Petersburg, Russian Federation), vol. 24, (Abstract Only), (1951), 1 pg.
Brinckerhoff, C. E., et al., “Matrix Metalloproteinases: A Tail of a Frog That Become a Prince”,Nature Reviews—Molecular Cell Biology, 3, (Mar. 2002), 207-214.
Chen, L., et al., “Crystal Structure of the Stromelysin Catalytic Doman at 2.0 A Resolution: Inhibitor-Induced Conformational Changes”,Journal of Molecular Biology, 293, (1999), 545-557.
Cohen, S. M., et al., “Mixed Hydroxypyridinonate Ligands as Iron Chelators”,American Chemical Society, 39, (Aug. 30, 2000), 4339-4346.
Cohen, S. M., et al., “Syntheses and Relaxation Properties of Mixed Gadolinium Hydroxypyridinonate MRI Contrast Agents”,American Chemical Society, 39, (2000), 5747-5756.
Cohen, S. M., et al., “Synthesis and Metal Binding Properties of Salicylate-, Catecholate-, and Hydroxypyridinonate-Functionalized Dendrimers”,Chem. Eur. J., 7(1), 2001 , 272-279.
Dilsiz, A. M., et al., “Synthesis and Evaluation of Antimicrobial Activity of New 3-Hydroxy-6-methyl-4-oxo-4H-pyran-2-carboxamide Derivatives”,Turkish Journal of Chemistry, 27 (6), (2003), 757-764.
Georg Iou, N. A., et al., “Human Immunodeficiency Virus Type 1 Replication Inhibition by the Bidentate Iron Chelators CP502 and CP511 IS Caused by Proliferation Inhibition and the Onset of Apoptosis”,European Journal of Clinical Investigation, 32((Issue S1), (2002), 91-96.
Gorden, A. E. V., et al., “Rational Design of Sequestering Agents for Plutonium and Other Actinides”,Chemical Reviews, 103(11), (2003), 4207-4282.
Hajduk, P. J., et al., “NMR-Based Modification of Matrix Metalloproteinase Inhibitors With Improved Bioavailability”,Journal of Medicinal Chemistry, 45, (2002), 5628-5639.
Hoeksema, H., et al., “The chemistry of rubradirin. III. The rubradiric acids and the structure of rubradirin”,Journal of Antibiotics, 32.(7), (Abstract Only), (1979), 1 pg.
Hoeksema, H., et al., “The chemistry of rubradirin. III. The rubradiric acids and the structure of rubradir

Affiliated with

Also associated with

Rating

Metalloprotein inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Metalloprotein inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Metalloprotein inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2716213